Orcas Are Terrorizing Sharks, And The Consequences Could Be Profound
A pair of orcas terrorizing white sharks off the coast of South Africa may have captured the popular imagination, but their activities may be quite damaging, new research suggests.
Port and Starboard, as the orcas (Orcinus orca) are known, have been documented hunting white sharks (Carcharodon carcharias) off the coast of South Africa for years, handily eviscerating them to feast on their nutritious livers, potentially reducing shark numbers in the area.
The impact of a declining shark presence has been difficult to determine, but we may be closer to an answer. Over the last few decades, white sharks have disappeared entirely from False Bay near the Cape of Good Hope – and the cascading effects of the loss of a top predator have been remarkable.
"The loss of this iconic apex predator has led to an increase in sightings of Cape fur seals and sevengill sharks, which in turn has coincided with a decline in the species that they rely on for food," says marine ecologist Neil Hammerschlag, formerly of the University of Miami.
"These changes align with long established ecological theories that predict the removal of a top predator leads to cascading effects on the marine food web."
An ecosystem is a delicate balance maintained by the interaction of the organisms that inhabit it. Although the predators at the top are considered scary by some, removing them from the environment has significant consequences.
Suppression of natural predators in Pando forest in Utah, for example, has allowed deer and elk to run riot, feasting on the ancient aspen colony and slowly killing it.
For more than 20 years, scientists have been monitoring wildlife populations in False Bay. This meant that they were able to see, in real time, the decline and ultimate disappearance of white sharks from the ecosystem there, and the consequent changes in populations of other species in the food web.
From 2000, scientists conducted standardized surveys of white shark sightings at Seal Island, and until around 2015, the shark population was pretty stable. After 2015, however, sightings started to fall dramatically; by 2018, there were no sharks to be seen.
The reason for this hasn't been officially confirmed. It's worth noting, however, that white sharks started washing up along the southern coast of South Africa, without their livers, in 2015 – attacks that would later be traced to Port and Starboard.
Although the cause of the shark disappearance is yet to be confirmed, we know the effects. White sharks prey on Cape fur seals (Arctocephalus pusillus pusillus). With no sharks around to keep their numbers in check, seal populations boomed.
At the same time, sevengill sharks (Notorynchus cepedianus) started appearing – large-bodied sharks that are both prey and competitor to white sharks.
As the numbers of Cape fur seals and sevengill sharks rose, populations of the species they prey upon in turn dramatically declined – small fish for the seals, and small sharks for the sevengills.
We know, based on other animal population booms, that a sudden increase in food competition between members of the same species can have dire consequences, with individuals taking greater risks to access food, and the weaker individuals starving when they are unable to compete.
It may take some time for the ecosystem to recover balance; and, once it does so, it could be very different from the ecosystem it was before.
Such changes are pretty normal in the natural world – after all, the world we live in today looks very different from the world of, say, 11,000 years ago, at the end of the last glacial period, or the world 70 million years ago, before the dinosaurs were eradicated.
However, understanding what drives such changes in the Anthropocene can help us try to minimize our own impact, and protect vulnerable habitats and the animals that need them to survive.
Port and Starboard have been observed hunting white sharks around Gansbaai and Mossel Bay, both further along the southern coast of South Africa.
The pair has also been sighted hunting in False Bay, although white sharks are not among the prey observed in that specific area. Nevertheless, it's reasonable to infer that their ongoing mischief at least plays a role in the changes at False Bay.
However, we cannot rule out overfishing, pollution, and shark cull programs as contributing factors, either. This is information that is relevant to understanding the wider impact of our own activities.
"Future work at this site would benefit from understanding if and how community structure and function may have been altered and the extent to which they will continue to change through time," the researchers write in their paper.
"While impacts of apex predator declines are difficult to detect in the wild, especially in marine environments, they are likely more widespread than recognized given the pace and extent of apex predator declines globally."
The research has been published in Frontiers in Marine Science.
Rock Used as a Doorstop For Decades Found to Be Worth Over $1 Million
Antarctic Iceberg Breaks Away to Reveal a Never-Before-Seen Ecosystem
Huge Trees Hiding in Plain Sight May Be a Species Totally New to Science

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
08-06-2025
- Yahoo
US researchers identify 230 new viruses with surprising effect on ocean health
Tiny ocean organisms like algae, amoebas, and flagellates are key to the marine food chain, and giant viruses that infect them can affect how they grow and survive. In some cases, these viruses may also lead to public health issues, such as harmful algal blooms. In the quest to unravel the varying kind of viruses found inside our planet's large water-bodies, scientists at University of Miami's Rosenstiel School of Marine, Atmospheric and Earth Science have uncovered 230 new giant viruses using advanced computing tools and ocean data. Researchers also identified 530 new proteins within these viruses, including nine linked to photosynthesis—suggesting the viruses may interfere with how their hosts convert sunlight into energy. According to Mohammad Moniruzzaman, co-author of the study and assistant professor in the university's Department of Marine Biology and Ecology, gaining a better understanding of the diversity and role of giant viruses in the ocean—and how they interact with algae and other microbes—could help predict and potentially manage harmful algal blooms, which pose risks to human health in Florida and around the world. "Giant viruses are often the main cause of death for many phytoplankton, which serve as the base of the food web supporting ocean ecosystems and food sources. The novel functions found in giant viruses could have biotechnological potential, as some of these functions might represent novel enzymes,"explained Moniruzzaman in a press release on University of Miami's website. Detecting giant viruses has proved to be a challenge so far because current computer methods had limitations. To overcome this, the research team created a new tool called BEREN—a program which offers a simple, all-in-one tool for identifying and classifying giant viruses in sequencing datasets To conduct their study, researchers gathered DNA sequencing data from nine major ocean sampling projects spanning the globe. Using BEREN they extracted giant virus genomes from this data. The scientists then analyzed the genomes using public gene function databases to identify the roles and activities encoded by these viruses. Following this, the results were compared to known giant virus genomes to uncover previously unknown functions and gain deeper insight into their diversity. Benjamin Minch, lead author of the study and a doctoral student at the Rosenstiel School, observed that giant viruses carry genes linked to important cellular functions like carbon metabolism and photosynthesis—processes usually found only in living cells. This finding suggests that these viruses have a significant role in altering their host's metabolism during infection and may impact key marine chemical cycles. The researchers used the University of Miami's Pegasus supercomputer at the Frost Institute for Data Science and Computing (IDSC) to process and assemble large metagenomes, often over a gigabase per sample, allowing them to reconstruct hundreds of microbial community libraries. Minch also noted that the study helped create a framework to improve tools for detecting new viruses, which could enhance efforts to monitor pollution and pathogens in waterways. Findings of the study have been published in the journal npj Viruses.
Yahoo
05-06-2025
- Yahoo
Massive Saharan dust cloud approaching Florida, Texas
Massive clouds of Sahara Desert dust are moving over the Atlantic toward Central and North America, with the possibility of reaching Florida and other states, including Texas, this week. The dust has covered parts of the Caribbean, including the Dominican Republic, Cuba and Haiti, and is projected to reach states along the Gulf Coast, like Mississippi and Alabama. 'The dust is due to a two to 2.5-mile-thick layer of the atmosphere, called the Saharan Air Layer, crossing over the Atlantic Ocean,' the National Oceanic and Atmospheric Administration (NOAA) said Wednesday. 'The warmth, dryness and strong winds associated with this layer have been shown to suppress tropical cyclone formation and intensification.' When the dust gets to the U.S., it can cause 'hazy skies as well as vivid sunrises and sunsets as the sun's rays scatter the dust in the atmosphere,' according to NOAA. The agency added that the dust can also 'suppress thunderstorm development over locations where the dust is especially thick.' The dust moves across the Atlantic from Africa every year, often called the Saharan Air Layer (SAL), which forms during late spring, summer and early fall, according to NOAA. 'SAL outbreaks can form when ripples in the lower-to-middle atmosphere, called tropical waves, track along the southern edge of the Sahara Desert and loft vast amounts of dust into the atmosphere,' said Jason Dunion, a University of Miami hurricane researcher who works with NOAA's Atlantic Oceanographic and Meteorological Laboratory. 'As the SAL crosses the Atlantic, it usually occupies a 2 to 2.5-mile-thick layer of the atmosphere with its base starting about 1 mile above the surface,' Dunion said Sunday. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
03-06-2025
- Yahoo
Philanthropic Donor Funds Cognition Therapeutics' Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies
Dr. James Galvin of the University of Miami to Serve as Lead Investigator First Site Initiated: Banner Sun Health Research Institute PURCHASE, N.Y., June 03, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the 'Company' or 'Cognition') (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced today it has received an anonymous philanthropic donation to substantially fund an expanded access program (EAP) for people with dementia with Lewy bodies (DLB). The generous donation comes from the family of a DLB patient who was treated with zervimesine in the Phase 2 SHIMMER study. Through this open-label EAP, participants will be provided with 100 mg of oral zervimesine to take daily for approximately one year. Banner Sun Health Research Institute in Arizona is the first of eight sites to be activated, with David Shprecher, DO Msci serving as primary investigator at the site. 'At Cognition, our ultimate goal is to create a therapy that changes lives. We are moving as rapidly as possible to onboard participating sites so that we can begin providing zervimesine to eligible patients this month,' stated Lisa Ricciardi, president and CEO of Cognition Therapeutics. 'Throughout the SHIMMER study, we have enjoyed a collaborative relationship with Drs. Galvin and Shprecher and their staffs. Their commitment and that of the Cognition team has been instrumental in launching the EAP so rapidly. Cognition would like to extend our sincere thanks to the benefactor and all stakeholders who made this program a reality.' Dr. James E. Galvin, MD, MPH, will act as lead investigator for the multi-center, open-label EAP. Dr. Galvin is the director of the Comprehensive Center for Brain Health at the University of Miami Miller School of Medicine and was the study director and principal investigator on the SHIMMER study grant from the National Institute of Aging. Dr. Galvin added, 'As a physician, it's always rewarding when you are able to offer a medication to a patient that may make a meaningful impact on their health. To have touched the anonymous donor's life so meaningfully that they felt compelled to support an expanded access program for so many people is humbling and rewarding. This program is a unique opportunity, and one that my colleagues and I are excited to be involved in.' Initially, the EAP will be able to accommodate approximately 30 individuals, who will be treated with 100 mg of once-daily oral zervimesine for approximately one year. Additional patients may be treated as funding and drug supply allows. The EAP will be open to eligible SHIMMER participants who completed the Phase 2 study as well as additional patients with a diagnosis of mild-to-moderate DLB who meet the criteria for this program. Eight U.S. sites, all of which were active in the SHIMMER study, were selected to participate in the EAP. Banner Sun Health Research Institute is the first participating site to be activated. Dr. Shprecher, Banner Health's movement disorder director and a clinical associate professor at the University of Arizona College of Medicine – Phoenix, will serve as the site's EAP investigator. Dr. Shprecher also served as an investigator for the Phase 2 SHIMMER study. About the EAPThe EAP will operate under a new protocol and will be referred to as COG1202. As an investigational medicine, zervimesine has not been approved by regulatory authorities. Therefore, the safety and efficacy of zervimesine have not been fully characterized and there may be risks associated with its use. If you are a patient or caregiver wishing to know more about this EAP for DLB, we encourage you to discuss this Program with your treating physician. If you are a treating physician and are seeking information about the zervimesine EAP or would like to request access for a patient, please contact EAP@ More information is available on under study identifier NCT06961760. About Cognition Therapeutics, Inc. Cognition Therapeutics, Inc., is a clinical-stage biopharmaceutical company discovering and developing innovative, small molecule therapeutics targeting age-related degenerative disorders of the central nervous system. We are currently investigating our lead candidate, zervimesine (CT1812), in clinical programs in dementia with Lewy bodies (DLB) and Alzheimer's disease, including the ongoing START study (NCT05531656) in early Alzheimer's disease. We believe zervimesine can regulate pathways that are impaired in these diseases though its interaction with the sigma-2 receptor, a mechanism that is functionally distinct from other approaches for the treatment of degenerative diseases. More about Cognition Therapeutics and our pipeline can be found at Forward-Looking Statements This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. All statements contained in this press release or made during the conference, other than statements of historical facts or statements that relate to present facts or current conditions, including but not limited to, statements regarding our product candidates, including zervimesine (CT1812), and any expected or implied benefits or results, including that initial clinical results observed with respect to zervimesine will be replicated in later trials and our clinical development plans, including statements regarding our clinical studies of zervimesine and any analyses of the results therefrom, are forward-looking statements. These statements, including statements relating to the timing and expected results of our clinical trials involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. In some cases, you can identify forward-looking statements by terms such as 'may,' 'might,' 'will,' 'should,' 'expect,' 'plan,' 'aim,' 'seek,' 'anticipate,' 'could,' 'intend,' 'target,' 'project,' 'contemplate,' 'believe,' 'estimate,' 'predict,' 'forecast,' 'potential' or 'continue' or the negative of these terms or other similar expressions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition, and results of operations. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond our control. Factors that may cause actual results to differ materially from current expectations include, but are not limited to: competition; our ability to secure new (and retain existing) grant funding; our ability to grow and manage growth, maintain relationships with suppliers and retain our management and key employees; our ability to successfully advance our current and future product candidates through development activities, preclinical studies and clinical trials and costs related thereto; uncertainties inherent in the results of preliminary data, pre-clinical studies and earlier-stage clinical trials being predictive of the results of early or later-stage clinical trials; the timing, scope and likelihood of regulatory filings and approvals, including regulatory approval of our product candidates; changes in applicable laws or regulations; the possibility that the we may be adversely affected by other economic, business or competitive factors, including ongoing economic uncertainty; our estimates of expenses and profitability; the evolution of the markets in which we compete; our ability to implement our strategic initiatives and continue to innovate our existing products; our ability to defend our intellectual property; the impacts of ongoing global and regional conflicts on our business, supply chain and labor force; our ability to maintain the listing of our common stock on the Nasdaq Global Market; and the risks and uncertainties described more fully in the 'Risk Factors' section of our annual and quarterly reports filed with the Securities & Exchange Commission and are available at These risks are not exhaustive and we face both known and unknown risks. You should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur, and actual results could differ materially from those projected in the forward-looking statements. Moreover, we operate in a dynamic industry and economy. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties that we may face. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. Contact Information: Cognition Therapeutics, Inc. info@ Casey McDonald (media) Tiberend Strategic Advisors, Inc. cmcdonald@ Mike Moyer (investors) LifeSci Advisors mmoyer@ This press release was published by a CLEAR® Verified in to access your portfolio